Phase II Study of Vinorelbine + TS-1 in Patients with EGFR-mutated Advanced Non-small Cell Lung Cancer
- Conditions
- EGFR-mutated non-small cell lung cancer
- Registration Number
- JPRN-UMIN000016765
- Lead Sponsor
- Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 37
Not provided
1 Patient with need of procedure for pleural effusion 2 Patient with need of drainage procedure for cardiac effusion 3 Patient with symptomatic brain metastasis 4 Patient with severe complications5 5 Patients with interstitial pneumonia or pulmonary fibrosis diagnosed by chest X-ray 6 Female Patient in or having a chance or planning of pregnancy or breast feeding 7 Male patient in planning to impregnate 8 Patient with active multiple cancers 9 Patients with history of drug hypersensitivity 10 Patients with histoly of hypersensitivity against vinorelbine or other vinca alkaloids 11 Patients with histoly of hypersensitivity against TS-1 or pyrimidine fluoride 12 Being treated with other pyrimidine fluoride 13 Being treated with flucytosine 14 Any patients judged by the investigator to be unfit to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method